- Home
- BH vs MRVI Comparison
BH vs MRVI Comparison
Compare BH & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- MRVI
- Stock Information
- Founded
- BH 1934
- MRVI 2020
- Country
- BH United States
- MRVI United States
- Employees
- BH N/A
- MRVI N/A
- Industry
- BH Restaurants
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- BH Consumer Discretionary
- MRVI Health Care
- Exchange
- BH Nasdaq
- MRVI Nasdaq
- Market Cap
- BH 712.7M
- MRVI 809.2M
- IPO Year
- BH N/A
- MRVI 2020
- Fundamental
- Price
- BH $264.55
- MRVI $5.33
- Analyst Decision
- BH
- MRVI Buy
- Analyst Count
- BH 0
- MRVI 10
- Target Price
- BH N/A
- MRVI $10.28
- AVG Volume (30 Days)
- BH 15.9K
- MRVI 1.7M
- Earning Date
- BH 11-08-2024
- MRVI 02-20-2025
- Dividend Yield
- BH N/A
- MRVI N/A
- EPS Growth
- BH 158.68
- MRVI N/A
- EPS
- BH 180.85
- MRVI N/A
- Revenue
- BH $361,664,000.00
- MRVI $276,920,000.00
- Revenue This Year
- BH N/A
- MRVI N/A
- Revenue Next Year
- BH N/A
- MRVI $2.85
- P/E Ratio
- BH $15.95
- MRVI N/A
- Revenue Growth
- BH N/A
- MRVI N/A
- 52 Week Low
- BH $145.95
- MRVI $4.28
- 52 Week High
- BH $266.30
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- BH 72.65
- MRVI 44.13
- Support Level
- BH $232.34
- MRVI $5.30
- Resistance Level
- BH $265.73
- MRVI $5.62
- Average True Range (ATR)
- BH 15.05
- MRVI 0.35
- MACD
- BH 1.58
- MRVI 0.03
- Stochastic Oscillator
- BH 96.26
- MRVI 27.45
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.